IN THE CLAIMS:

Please cancel claims 31-43 without prejudice to or disclaimer of the subject matter recited therein.

Please add claims 44-56 as follows:

44. (new) An isolated polynucleotide comprising:

(a) a nucleotide sequence encoding a polypeptide having the activity of cysteinyl-tRNA synthetase, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:10 have at least 80% identity based on the Clustal alignment method, or

(b) the complement of the nucleotide sequence.

45. (new) The polynucleotide of claim 44, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:10 have at least 85% identity based on the Clustal alignment method.

46. (new) The polynucleotide of claim 44, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:10 have at least 90% identity based on the Clustal alignment method.

47. (new) The polynucleotide of claim 44, wherein the amino acid sequence of the polypeptide and the amino acid sequence of SEQ ID NO:10 have at least 95% identity based on the Clustal alignment method.

C3

48. (new) The polynucleotide of claim 44, wherein the nucleotide sequence comprises the nucleotide sequence of SEQ ID NO:9.

49. (new) The polynucleotide of claim 44, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:10.

50. (new) A chimeric gene comprising the polynucleotide of claim 44 operably linked to a regulatory sequence.

51. (new) An isolated polynucleotide containing 30 nucleotides, wherein the nucleotide sequence containing 30 nucleotides is comprised by the polynucleotide of claim 44.

52. (new) A method for transforming a cell comprising transforming a cell with the polynucleotide of claim 44.

53. (new) A cell comprising the chimeric gene of claim 50.